Literature DB >> 32946322

2018 FIGO Staging Classification for Cervical Cancer: Added Benefits of Imaging.

Miriam Y Salib1, James H B Russell1, Victoria R Stewart1, Siham A Sudderuddin1, Tara D Barwick1, Andrea G Rockall1, Nishat Bharwani1.   

Abstract

Cervical cancer is the fourth most common cancer in women of all ages worldwide. The disease is staged using the International Federation of Gynecology and Obstetrics (FIGO) system, which was updated in 2018. The authors explain the key changes from the 2009 version and the rationale behind them. The changes have been made to reflect common clinical practice, differentiate prognostic outcomes, and guide treatment stratification. Treatment options are dependent on the stage of disease and include fertility-sparing and non-fertility-sparing surgical options as well as chemoradiotherapy for locally advanced disease. The updated FIGO staging gives added importance to MRI as a method of accurately measuring tumor size and depicting the presence of parametrial involvement. With the inclusion of lymph node involvement in the updated 2018 FIGO staging, cross-sectional imaging-and in particular, fluorodeoxyglucose PET/CT-has an increasing role in the depiction of nodal disease. Understanding the radiologic techniques used, the literature supporting them, and common imaging pitfalls ensures accurate staging of disease and optimization of treatment. ©RSNA, 2020 See discussion on this article by Javitt (pp 1823-1824).

Entities:  

Mesh:

Year:  2020        PMID: 32946322     DOI: 10.1148/rg.2020200013

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  6 in total

1.  Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer.

Authors:  Mansur A Ghani; Joy Liau; Ramez Eskander; Loren Mell; Tahir Yusufaly; Sebastian Obrzut
Journal:  J Comput Assist Tomogr       Date:  2022-08-16       Impact factor: 2.081

2.  Pretreatment Radiologically Enlarged Lymph Nodes as a Significant Prognostic Factor in Clinical Stage IIB Cervical Cancer: Evidence from a Taiwanese Tertiary Care Center in Reaching Consensus.

Authors:  Chia-Hao Liu; Szu-Ting Yang; Wei-Ting Chao; Jeff Chien-Fu Lin; Na-Rong Lee; Wen-Hsun Chang; Yi-Jen Chen; Peng-Hui Wang
Journal:  Diagnostics (Basel)       Date:  2022-05-14

3.  Application of an Autophagy-Related Gene Prognostic Risk Model Based on TCGA Database in Cervical Cancer.

Authors:  Huadi Shi; Fulan Zhong; Xiaoqiong Yi; Zhenyi Shi; Feiyan Ou; Zumin Xu; Yufang Zuo
Journal:  Front Genet       Date:  2021-02-09       Impact factor: 4.599

4.  Incidence, clinical risk and prognostic factors for liver metastasis in patients with cervical cancer: a population-based retrospective study.

Authors:  Hang Liu; Xiangsen Ye; Di Li; Qian Yao; Yan Li
Journal:  BMC Cancer       Date:  2021-04-16       Impact factor: 4.430

5.  Prognostic Analysis and Comparison of the 2014 and 2018 International Federation of Gynecology and Obstetrics Staging System on Overall Survival in Patients with Stage IIB-IVA Cervix Carcinoma.

Authors:  Tao Song; Hong'en Xu; Lei Shi; Senxiang Yan
Journal:  Int J Womens Health       Date:  2022-03-06

6.  Robotic Staging of Cervical Cancer With Simultaneous Detection of Primary Pelvic and Secondary Para-Aortic Sentinel Lymph Nodes: Reproducibility in a First Case Series.

Authors:  Philippe Van Trappen; Eveline De Cuypere; Nele Claes; Sarah Roels
Journal:  Front Surg       Date:  2022-06-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.